TARGETING ANTIBODY-POLYETHYLENE GLYCOL-SIRNA DRUG CONJUGATE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 27, 2025
app pub date -
Jul 20, 2022
filing date -
Jul 20, 2022
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
Disclosed in the present invention are a targeting antibody-polyethylene glycol-siRNA drug conjugate, and a preparation method therefor and the use thereof. The ligand drug conjugate has a structure as represented by general formula (I). Further disclosed in the present invention is that a polyethylene glycol derivative having excellent biocompatibility is used as a linker, and targeted delivery of specific CFD-siRNA is achieved using binding specificity of an antibody and an antigen. The drug conjugate has high biocompatibility and minor side effects, can effectively inhibit CFD gene expression, and provides a new choice for preventing or treating CFD-related diseases.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully